Phase 2 data from the ongoing HIBISCUS study shows promise that investigational ... - Morningstar
Phase 2 HIBISCUS study results indicate etavopivat may reduce vaso-occlusive crises in sickle cell disease, with trends of reduced VOC incidence over 52 weeks and increased hemoglobin response at 24 weeks vs. placebo. Results to be confirmed in phase 3 HIBISCUS trial.
Related Clinical Trials
Reference News
Etavopivat, in the phase 2 HIBISCUS trial, showed improvements in vaso-occlusive crises, fatigue, hemolysis, and hemoglobin levels in sickle cell disease patients, with a significant reduction in VOCs in per-protocol analysis. The drug's novel mechanism of action as an erythrocyte pyruvate kinase activator suggests potential benefits for SCD treatment.
Phase 2 HIBISCUS study results indicate etavopivat may reduce vaso-occlusive crises in sickle cell disease, with trends of reduced VOC incidence over 52 weeks and increased hemoglobin response at 24 weeks vs. placebo. Results to be confirmed in phase 3 HIBISCUS trial.
Novo Nordisk announced 52-week results from the phase 2 HIBISCUS study of etavopivat in sickle cell disease, showing a trend toward reduced vaso-occlusive crises and increased hemoglobin response. Results will be confirmed in the phase 3 HIBISCUS trial.
Phase 2 data from the HIBISCUS study indicates etavopivat may reduce vaso-occlusive crises in sickle cell disease, with a trend towards lower VOC incidence and increased hemoglobin response. Results will be further tested in the phase 3 HIBISCUS trial.
Etavopivat reduced annualized vaso-occlusive crises rate vs. placebo in sickle cell disease, increased hemoglobin levels, reduced fatigue, and improved hemolysis markers, according to HIBISCUS trial data presented at ASH Annual Meeting and Exposition.